



SCIENCE OF TODAY  
HOPE FOR TOMORROW

**CZECH  
REPUBLIC**

# **Best of ASTRO 2018**

## **Czech Republic**

**18. 3. 2019**

**Kongresové centrum Kunětická Hora Dříteč**



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

09:15 - 09:30     **Welcome**  
Martin Dolezel

09:30 - 10:20     **Track 1 – Gastrointestinal (Renata Soumarova)**

**Abstract 1: (LBA8)** Preoperative Chemoradiotherapy Potentially Improves Outcome for (borderline) Resectable Pancreatic Cancer: Preliminary Results of the Dutch Randomized Phase III Preopanc Trial

**Abstract 2: (55)** Capecitabine Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin with Concurrent Radiation Therapy in the Treatment of Gastric Cancer after D2 Gastrectomy

**Abstract 3: (56)** A Prospective Study Assessing Early Cardiotoxicity after Trimodality Therapy for Esophageal Cancer

**Abstract 4: (57)** A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma

**Abstract 5: (129)** Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study

**Abstract 6: (275)** Predictors of Radiation-Induced Liver Disease in Patients with Hepatocellular Carcinoma Undergoing Proton Beam Therapy

**Abstract 7: (276)** Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer

**Abstract 8: (279)** DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated with Veliparib, Gemcitabine and Radiation Therapy



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

10:20 - 11:00    **Track 2 – Gynecological (Martina Kubecova)**

**Abstract 1: (166)** Pre-Treatment [F-18]FDG-PET SUVmax as a Prognostic and Radiogenomic Marker in Cervical Cancer

**Abstract 2: (167)** Global Immune Profiling of Cervical Tumors Reveals a Protective T-Follicular Helper Cell Response Induced by Radiation Therapy

**Abstract 3: (168)** Molecular Targeting to Expand the Therapeutic Ratio in Women with Curable Cervical Cancer

**Abstract 4: (171)** Chemoradiation Therapy for Vulvar Squamous Cell Carcinoma: Does p16-Positivity Predict for Better Response Rates and Outcomes?

**Abstract 5: (172)** A Prospective Study of IMRT Versus 3D-CRT for Post-Operative Cervical Cancer Patients.

**Abstract 6: (174)** Small Cell Carcinoma of the Cervix: Definitive Chemoradiation for Locally Advanced Disease



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

11:15 - 12:05 **Track 3 – Genitourinary (Karel Odrazka)**

**Abstract 1: (LBA5)** Short Term Androgen Deprivation Therapy Without or with Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

**Abstract 2: (3)** Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

**Abstract 3: (4)** Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large-Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials

**Abstract 4: (60)** 10-Year Update of a Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer

**Abstract 5: (62)** Long-Term Update of NRG Oncology RTOG 94-08

**Abstract 6: (199)** International Multicenter Validation of an Intermediate-Risk Subclassification of Men Treated with Radical Treatment Without Hormone Therapy

**Abstract 7: (205)** Toxicity and Biochemical Outcomes after Dose Intensified Post-Operative Radiation Therapy for Prostate Cancer: A Randomized, Controlled, Phase 3 Trial

**Abstract 8: (217)** Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study

**Abstract 9: (297)** Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy

**Abstract 10: (299)** Local Failure and Gleason Score 9-10 Disease Independently Predict for Survival Outcomes: A Meta-Analysis of Six Randomized Trials



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

12:05 - 12:45    **Track 4 – Lung (Jakub Cvek)**

**Abstract 1: (LBA3)** Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial

**Abstract 2: (LBA10)** PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

**Abstract 3: (15)** A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-Small Cell Lung Cancer. Japan Clinical Oncology Group (JCOG0403): Long Term Follow-up Results

**Abstract 4: (20)** An Externally Validated Nomogram for Predicting Distant Metastasis after Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Implications for Adjuvant Systemic Therapy

**Abstract 5: (21)** Local Control Analyses of Pulmonary Oligometastases Treated By Stereotactic Body Radiation Therapy (SBRT) from a Multi-institutional Survey in Japan

**Abstract 6: (189)** Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

**14:00 - 14:30 Track 5 – Best of the Rest (Martin Dolezel)**

**Abstract 1:** An individual-patient pooled analysis from the international radiosurgery oncology consortium for kidney (IROCK)

**Abstract 2:** SABR-COMET: Stereotactic Radiation for the Comprehensive Treatment of Oligometastatic Cancers – Results of a Randomized Study

**Abstract 3:** ASTRO Guidelines Highlight Session

- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
- Radiation Therapy for Pancreatic Cancer: An ASTRO Evidence-Based Guideline

**Abstract 4:** First-In-Human Clinical Experience With Real-Time Tumor Targeting Via MLC Tracking for Stereotactic Radiotherapy of Lung Cancer



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

14:30 - 15:20    **Track 6 – Breast (Jiri Petera)**

**Abstract 1: (LBA1)** Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804

**Abstract 2: (LBA2)** FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015)

**Abstract 3: (85)** Reconstruction Failure Rates in Breast Cancer Patients with Two-Stage Expander/Implant Reconstruction Receiving Regional Nodal Irradiation with VMAT: Early Results of a Phase II Trial

**Abstract 4: (89)** Risk of Radiation Pneumonitis Following Individualized Modern Radiation Therapy with IMRT, a Breath-Holding Technique and Prone Positioning for Breast Cancer

**Abstract 5: (90)** Comparing 10 Year Outcomes in Radiated Patients with Breast Autologous Reconstruction (AR) or Tissue Expander/Implant Based Reconstruction (TE/I)

**Abstract 6: (132)** Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer

**Abstract 7: (133)** Gene Expression Changes Predict Acute and Late Toxicity to Combined PARP1 Inhibition and Radiation (RT) in High Risk Breast Cancer Patients- Results of the Biomarker Analysis of TBCRC 024

**Abstract 8: (136)** Phase I Trial of Stereotactic Body Radiation Therapy(SBRT) to Multiple Metastatic Sites: A NRG Oncology Study

**Abstract 9: (162)** Influence of Hypofractionated Radiation Therapy Following Mastectomy on Complication in Breast Cancer Patients Undergoing Two-Stage Prosthetic Breast Reconstruction



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

15:30 - 16:20 **Track 7 - Head and Neck (Milan Vosmik)**

**Abstract 1: (LBA4)** NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx

**Abstract 2: (LBA6)** Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal Cancer

**Abstract 3: (1)** Eliminating Post-operative Radiation to the Pathologically Node Negative Neck: Long-Term Results of a Prospective Phase II Study

**Abstract 4: (40)** The Influence of Smoking and Age on Pathologic Features and Outcomes in Oral Cavity Squamous Cell Cancer: A Multi-institutional Collaborative Study

**Abstract 5: (41)** Validating the AJCC 8th Edition of the Oral Cavity Cancer Staging System: A Multi-institutional Collaborative Study

**Abstract 6: (43)** Margin Status, Lymphovascular Invasion, and Number of Neck Levels Involved Predict Distant Failure in p16+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Transoral Robotic Surgery (TORS)

**Abstract 7: (223)** A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)

**Abstract 8: (228)** Smoking Cessation Had Good Impact on Clinical Outcomes in Patients with Head and Neck Squamous Cell Carcinoma Receiving Curative Chemoradiotherapy

**Abstract 9: (258)** The Long-term Results of Adding Chemotherapy to Intensity-Modulated Radiation Therapy in the Treatment of Stage II Nasopharyngeal Carcinoma - A Multicenter Phase 2 Study





SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

16:20 - 17:00    **Track 8 – Central Nervous System**  
**(Pavel Slampa, Tomas Kazda)**

**Abstract 1: (LBA9)** Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001

**Abstract 2: (92)** Elevated MGMT Gene Expression Is Independently Associated with Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma

**Abstract 3: (96)** A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis

**Abstract 4: (98)** Risk Factors for Progression of Low Grade Glioma Following Gross Total Resection and Observation in the Molecular Era

**Abstract 5: (290)** Improved Survival Following Immunotherapy in Patients with Lung and Melanoma Primaries Metastatic to the Brain Treated with Upfront Stereotactic Radiosurgery

**Abstract 6: (291)** Preoperative Radiosurgery For Resected Brain Metastases: Updated Analysis of Efficacy and Toxicity Of A Novel Treatment Paradigm

**Abstract 7: (293)** A Phase II Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases

**Abstract 8: (1024)** Dosimetric Predictors of Cognitive Decline in Attention and Processing Speed after Fractionated Brain Radiation Therapy



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH  
REPUBLIC

**Kontakt:** [dolezelm@email.cz](mailto:dolezelm@email.cz)

Doc. MUDr. Martin Doležel, Ph.D.  
KOC Pardubického kraje, Kyjevská 44,  
532 03 Pardubice  
[www.multiscan.cz](http://www.multiscan.cz)

Kongresové centrum Kunětická Hora Dříteč  
Dříteč 155, 533 05  
GPS: 50°6'41.669"N, 15°49'9.128"E  
<http://grkh.cz/kongres/>

Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č.16,  
bude ohodnocena příslušným počtem kreditů.

Výše účastnického poplatku je 150 Kč (platba na místě).

Prosím o elektronické přihlášení na mail ([dolezelm@email.cz](mailto:dolezelm@email.cz)),  
nejpozději do **12. 3. 2019**.